A Study of the Effects of Paroxetine on the Pharmacokinetics of Paliperidone ER
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of a CYP2D6 inhibitor, paroxetine, on
the pharmacokinetics of a single dose of orally administered paliperidone ER and to evaluate
the safety and tolerability of both treatments in healthy men
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.